On April 28, the company released its 2022 annual report and 2023 quarterly report. In 2022, the company achieved operating income of 4.535 billion yuan, an increase of 22.60 % year-on-year. Achieved a net profit of 460 million yuan attributable to shareholders of listed companies, a year-on-year increase of 2.28 % ; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 449 million yuan, up 6.15 % year-on-year ; weighted average return on equity 14.83 % ; the company 's basic earnings per share is 1.35 yuan. In the first quarter of 2023, operating income reached 1.23 billion yuan, an increase of 2.51 % year-on-year ; the net profit attributable to shareholders of listed companies was 149 million yuan, an increase of 7.41 % year-on-year ; the company 's basic earnings per share is 0.45 yuan.
The main achievements in 2022 are as follows : the company 's preparation business has achieved steady growth, and the sales volume of main raw drug products has increased, which has had a positive impact on the company 's performance. Although affected by the technical transformation of safety and environmental protection maintenance, on the whole, in 2022, the company 's overall operating income and net profit will achieve steady growth, and the operating net cash flow will achieve substantial growth, with good operating conditions.
In 2022, the company 's management and management will closely focus on the annual business objectives determined at the beginning of the year, strive to overcome various unfavorable factors, emancipate the mind in management innovation, speed up efficiency, actively take effective measures, concentrate on all aspects of advantages, take the market as an opportunity, grasp customer needs in time, highlight technical services, constantly improve product differentiation, strengthen internal management, optimize resource allocation, continuously improve efficiency, strengthen the expansion of foreign markets and channels, and deepen the cooperation and exchange of multinational corporations. The company 's main business matters in 2022 are : completing the equity incentive reservation registration ; the sustainable development of crude drug enters the fast lane ; complete the three phases of equity incentive reservation in 2018 and the first phase of equity incentive in 2021.
